Efficacy of Ventavis Used in Real-life Setting.
NCT01355380 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 55
Last updated 2017-10-17
Summary
This is a registry of patients diagnosed with pulmonary arterial hypertension, scheduled for treatment with Ventavis.
Typical clinical measures and quality of life will be prospectively followed in 12 months period.
Conditions
Interventions
- DRUG
-
Inhaled iloprost (Ventavis, BAYQ6256)
Patients treated with inhaled iloprost (Ventavis) 2.5 or 5 micrograms 6-9 times daily
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bayer Study Director · Bayer
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-08-05
- Primary Completion
- 2016-04-28
- Completion
- 2016-09-22
Countries
- Poland
More Related Trials
-
Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients
NCT01781052 ·Status: COMPLETED
-
Hypertension Study of Ventavis® Inhalation Therapy in the Treatment of Patients With Pulmonary Arterial Hypertension (VENIS)
NCT01062282 ·Status: COMPLETED
-
Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
NCT01894035 ·Status: COMPLETED
-
Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)
NCT02825160 ·Status: COMPLETED
-
Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study
NCT01469169 ·Status: COMPLETED ·Phase: PHASE3
-
Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)
NCT00882947 ·Status: COMPLETED
-
Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension
NCT00414687 ·Status: COMPLETED ·Phase: PHASE2
-
Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)
NCT02826252 ·Status: COMPLETED
-
Ventavis® Registry Protocol
NCT00902603 ·Status: TERMINATED
-
Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)
NCT01437878 ·Status: TERMINATED ·Phase: PHASE2
-
Comparative PK PD Study in PAH Patients (Fox vs. I-Neb)
NCT02032836 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension
NCT01054105 ·Status: COMPLETED
-
Use of Ventavis in Patients With Postembolic Residual Pulmonary Hypertension
NCT02238535 ·Status: UNKNOWN ·Phase: PHASE2
-
Educational Training Influence in Patients With PAH(Pulmonary Artery Hypertension) on Inhaled Ventavis Treatment Adherence Evaluated Trough INSIGHT System
NCT01468545 ·Status: COMPLETED
-
VentaProst Versus Conventionally-Administered Aerosolized Epoprostenol in Patients Undergoing Cardiac Surgery With CPB
NCT03122730 ·Status: COMPLETED ·Phase: PHASE2
-
Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.
NCT00640315 ·Status: COMPLETED ·Phase: PHASE1
-
Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis
NCT00109681 ·Status: COMPLETED ·Phase: PHASE2
-
Iloprost-Study: Comparison of Nitric Oxide to Iloprost (Ventavis) for Treatment of Pulmonary Hypertension in Children After Cardiopulmonary Bypass Surgery
NCT00235521 ·Status: COMPLETED ·Phase: NA
-
LenusPro Pump in PAH Treated With Treprostinil
NCT02889315 ·Status: UNKNOWN
-
Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction
NCT00458042 ·Status: TERMINATED ·Phase: PHASE4
-
This Study Tests the Safety of Inhaled BAY1237592, How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
NCT03754660 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of Vasodilator Response of Inhaled Epoprostenol and Inhaled Nitric Oxide
NCT04231084 ·Status: COMPLETED ·Phase: PHASE4
-
The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension
NCT00302211 ·Status: TERMINATED ·Phase: PHASE3
-
Iloprost in High Risk Cardiac Surgical Patients
NCT00927654 ·Status: COMPLETED ·Phase: PHASE3
-
Acute Response of Iloprost Inhalation Using the Breelib Nebulizer in Pulmonary Arterial Hypertension
NCT03365479 ·Status: COMPLETED ·Phase: NA